secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0001576280-23-000019
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q4 revenue $126.9M (+17% YoY); net loss widens to $139.9M; guides FY23 rev $525-540M
--------------------------------------------------------------------------------

- Q4 revenue $126.9M (+17% YoY); full-year revenue $449.5M (+20% YoY).
- Q4 clinical test volume 36,000 (+41% YoY); biopharma 8,200 (+24% YoY).
- Q4 net loss $139.9M ($1.36/share) vs $90.9M ($0.89) prior year; non-GAAP net loss $119.6M.
- FY23 revenue guidance $525-540M (17-20% growth); expects free cash outflow ~$350M.
- ECLIPSE study for Shield CRC screening showed 83% sensitivity, 90% specificity; FDA approved Guardant360 CDx for breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628023000019/0001576280-23-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628023000019/gh-20230223.htm
  HTML page:      https://secwatch.observer/filing/0001576280-23-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer